In this review:
Abiraterone + prednisone for metastatic castration-naive prostate cancer
ADT + enzalutamide in metastatic hormone-sensitive prostate cancer
Darolutamide in nmCRPC
Nivolumab + ipilimumab for mCRPC
Pembrolizumab + olaparib mCRPC
Stereotactic body radiotherapy vs fractionated external beam radiotherapy
Avelumab + axitinib in advanced RCC
Pembrolizumab + axitinib for locally advanced or mRCC
Pembrolizumab for high-risk NMIBC unresponsive to BCG
Sacituzumab govitecan in previously treated metastatic urothelial cancer
Please login below to download this issue (PDF)